Pilot Study on the Effect of Intracoronary Cryotherapy on Stabilization of Vulnerable Plaque at Risk of Rupture

NCT04857580 | Withdrawn DMC

• 1 other identifier: CT-CD-P01-1
• Study Type: interventional
• Target: N/A
• Locations: 2 countries
• Sites: 3

Brief Summary

Atherosclerosis is a progressive inflammatory disease of the large and medium sized arteries, which is characterized by the formation of plaques in the vessel wall. The morphology and composition of the plaque play a major role in its stability during the development of the disease. The CTS system allows to deliver coronary cryotherapy intended for stabilization of vulnerable plaque with non-significant stenosis. Vulnerable plaque at high risk of rupture will be assessed by NIRS-IVUS imaging modality in patients with Acute Coronary Syndrome (ACS). The ICEBERG study is an early feasibility single arm study enrolling a maximum of 45 patients. After enrolment of the first 5 patients in the First-in-Man safety cohort, the trial will enroll and randomize 40 eligible lesions in the randomized cohort of which 20 will be treated with cryotherapy.

Conditions

Acute Coronary Syndrome

Outcome Measures

Primary Outcomes (2)

• Cryotherapy procedure related complication

  Any cryotherapy procedure related complication defined as coronary artery dissection, acute vessel closure, ischemia, arrythmia, need for bailout stenting, or any Major Adverse Cardiac Events (MACE) adjudicated to the index lesion

  90 days

• Optical Coherence Tomography (OCT)-assessed fibrous cap thickness

  Change in Optical Coherence Tomography (OCT)-assessed fibrous cap thickness from index lesion.

  90 days

Secondary Outcomes (3)

• Cryotherapy related complication

  9 months

• Device success

  Baseline

• Cryotherapy/lesion procedure success

  Baseline

Study Arms (2)

CTS device

EXPERIMENTAL

Device: CTS Device

Control

NO INTERVENTION

Interventions

CTS Device DEVICE

Coronary cryotherapy is delivered locally on eligible lesions randomized to the treatment using the CTS System.

CTS device

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Men or women at least 18 years old.
• Acute cardiac pain/angina consistent with acute coronary syndrome eligible for coronary angiography meeting one of the following criteria:
• Non ST-segment elevation myocardial infarction (NSTEMI) with rise/fall of cardiac enzymes (troponin I or T) with at least one value above the 99th percentile of the upper reference limit requiring Percutaneous Coronary Intervention (PCI) within 72 hours from diagnosis
• Stabilized ST-segment elevation myocardial infarction (STEMI) with at least one value above the 99th percentile of the upper reference limit requiring PCI within \< 12 hours from symptoms onset.
• Unstable angina with new or worsening angina symptoms over the last 2 weeks requiring PCI within 72 hours.
• Patient must have one, two or three-vessel disease in native coronary arteries.
• PCI of the culprit lesion on all patients.
• At least one lesion meeting the criteria below:
• Located in a non-culprit vessel, or proximal to the culprit lesion if located in the culprit vessel with at least 10 mm distance from the culprit lesion.
• Lesion stenosis ≤ 70% of the reference vessel diameter by visual assessment on coronary angiogram.
• Plaque-level maxLCBI4mm ≥ 325 by NIRS (Near-Infrared Spectroscopy).
• Plaque burden ≥ 65% by IVUS (IntraVascular UltraSound).
• Not intended for revascularization based on angiographic criteria and negative physiology assessment (FFR\>0.80 or iFR/RFR\>0.89).
• Lesion-level balloon to artery ratio \> 1.0.
• Lesion length ≤ 20 mm.

You may not qualify if:

• Unstable patients (cardiogenic shock, hypotension needing inotropes, hypoxia needing intubation, refractory ventricular arrhythmias, and IABP).
• Patients with ongoing ST-segment elevation myocardial infarction.
• Patients that had a procedural complication during the PCI procedure, such as coronary dissection, perforation or a complication that would necessitate immediate and/or unplanned surgical revascularization.
• History of Coronary Artery Bypass Graft (CABG) or planned CABG within 12 months after the index procedure.
• Known ejection fraction \< 30%.
• Known severe valvular heart disease.
• Known severe renal insufficiency (eGFR \<30 ml/min/1.72 m2).
• Any life-threatening conditions or medical comorbidity resulting in life expectancy \< 12 months.
• Participation in any investigational study that has not yet reached its primary endpoint.
• Women who are pregnant or lactating, or NOT surgically sterile (tubal ligation or hysterectomy) or NOT postmenopausal for at least 6 months or women with childbearing potential without effective contraception (pill, patch, ring, diaphragm, implant and intrauterine device).
• Visible distal embolization/no-reflow following culprit PCI.
• Left main coronary artery disease (visual diameter stenosis \> 50%).
• Stent thrombosis/restenosis as a culprit lesion.
• Index lesion involving a bifurcation.
• Angiographic evidence of severe calcification and/or marked tortuosity of the index vessel and/or lesion.

Sponsors & Collaborators

• Cryotherapeutics SA: lead

Study Sites (3)

Rigshospitalet

Copenhagen, Denmark

Location

Zealand University Hospital

Roskilde, 4000, Denmark

Location

Skåne University Hospital

Lund, 22242, Sweden

Location

Related Publications (2)

• Erlinge D, Maehara A, Ben-Yehuda O, Botker HE, Maeng M, Kjoller-Hansen L, Engstrom T, Matsumura M, Crowley A, Dressler O, Mintz GS, Frobert O, Persson J, Wiseth R, Larsen AI, Okkels Jensen L, Nordrehaug JE, Bleie O, Omerovic E, Held C, James SK, Ali ZA, Muller JE, Stone GW; PROSPECT II Investigators. Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study. Lancet. 2021 Mar 13;397(10278):985-995. doi: 10.1016/S0140-6736(21)00249-X.

  PMID: 33714389 BACKGROUND

• Stone GW, Maehara A, Ali ZA, Held C, Matsumura M, Kjoller-Hansen L, Botker HE, Maeng M, Engstrom T, Wiseth R, Persson J, Trovik T, Jensen U, James SK, Mintz GS, Dressler O, Crowley A, Ben-Yehuda O, Erlinge D; PROSPECT ABSORB Investigators. Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque. J Am Coll Cardiol. 2020 Nov 17;76(20):2289-2301. doi: 10.1016/j.jacc.2020.09.547. Epub 2020 Oct 15.

  PMID: 33069847 BACKGROUND

MeSH Terms

Conditions

Acute Coronary Syndrome

Condition Hierarchy (Ancestors)

Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 13, 2021
• First Posted: April 23, 2021
• Study Start: September 1, 2021
• Primary Completion: December 15, 2022
• Study Completion: December 15, 2022
• Last Updated: February 17, 2023

Record last verified: 2023-02

Data Sharing

• IPD Sharing: Will not share

Locations

DK (2); SE (1)